Overview

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation
Phase:
Phase 2
Details
Lead Sponsor:
University of Göttingen
Treatments:
Alemtuzumab